Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH-30236 in relapsed/refractory AML and higher-risk MDS
NCT06501196Phase 1Recruiting
- Sponsor
- BlossomHill Therapeutics
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BH-30236 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by BlossomHill Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
BH-30236
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06501196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501196.